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A B S T R A C T
Background
Pericarditis is the inﬂammation of the pericardium, the membranous sac surrounding the heart. Recurrent pericarditis is the most
common complication of acute pericarditis, causing severe and disabling chest pains. Recurrent pericarditis affects one in three patients
with acute pericarditis within the ﬁrst 18 months. Colchicine has been suggested to be beneﬁcial in preventing recurrent pericarditis.
Objectives
To review all randomised controlled trials (RCTs) that assess the effects of colchicine alone or combined, compared to any other
intervention to prevent further recurrences of pericarditis, in people with acute or recurrent pericarditis.
Search methods
We searched the following bibliographic databases on 4 August 2014: Cochrane Central Register of Controlled Trials (CENTRAL,
Issue 7 of 12, 2014 on The Cochrane Library), MEDLINE (OVID, 1946 to July week 4, 2014), EMBASE (OVID, 1947 to 2014 week
31), and the Conference Proceedings Citation Index - Science on Web of Science (Thomson Reuters) 1990 to 1 Aug 2014. We did
not apply any language or time restrictions.
Selection criteria
RCTs of people with acute or recurrent pericarditis who are receiving colchicine compared to any other treatment, in order to prevent
recurrences.
Data collection and analysis
Two review authors independently selected trials for inclusion, extracted data and assessed the risk of bias. The ﬁrst primary outcome
was the time to recurrence, measured by calculating the hazard ratios (HRs). The second primary outcome was the adverse effects of
colchicine. Secondary outcomes were the rate of recurrences at 6, 12 and 18 months, and symptom relief.
Main results
We included four RCTs, involving 564 participants in this review. We compared the effects of colchicine in addition to a non-steroidal
anti-inﬂammatory drug (NSAID) such as ibuprofen, aspirin or indomethacin to the effects of the NSAID alone. Two comparable
trials studied the effects of colchicine in 204 participants with recurrent pericarditis and two trials studied 360 people with acute
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pericarditis. All trials had a moderate quality for the primary outcomes. We identiﬁed two on-going trials; one of these trials examines
acute pericarditis and the other assesses recurrent pericarditis.
There was moderate quality evidence that colchicine reduces episodes of pericarditis in people with recurrent pericarditis over 18
months follow-up (HR 0.37; 95% conﬁdence interval (CI) 0.24 to 0.58). It is expected that at 18 months, the number needed to treat
(NNT) is 4. In people with acute pericarditis, there was moderate quality evidence that colchicine reduces recurrence (HR 0.40; 95%
CI 0.27 to 0.61) at 18 months follow-up. Colchicine led to a greater chance of symptom relief at 72 hours (risk ratio (RR) 1.4; 95%
CI 1.26 to 1.56; low quality evidence). Adverse effects were mainly gastrointestinal and included abdominal pain and diarrhoea. The
pooled RR for adverse events was 1.26 (95% CI 0.75 to 2.12). While the number of people experiencing adverse effects was higher
in the colchicine than the control groups (9% versus 7%), the quality of evidence was low owing to imprecision, and there was no
statistically signiﬁcant difference between the treatment groups (P = 0.42). There was moderate quality evidence that treatment with
colchicine led to more people stopping treatment due to adverse events (RR 1.87; 95% CI 1.02 to 3.41).
Authors’ conclusions
Colchicine, as adjunctive therapy to NSAIDs, is effective in reducing the number of pericarditis recurrences in patients with recurrent
pericarditis or acute pericarditis. However, evidence is based on a limited number of small trials. Patients with multiple resistant
recurrences were not represented in any published or on-going trials, and it is these patients that are in the most need for treatment.
P L A I N L A N G U A G E S U M M A R Y
Systematic review of randomised controlled trials about the efficacy and safety of colchicine in people with pericarditis
Pericarditis is the inﬂammation and swelling of the tissue covering the outer layer of the heart. Pericarditis causes severe and disabling
chest pain and fever, however the main issue is the repeated recurrence of pericarditis attacks. Colchicine is an ancient medication that
has been used in the treatment of other inﬂammatory diseases such as gout.
We wanted to discover whether colchicine alone or added to other medications is better or worse than alternative therapies in preventing
pericarditis. We have reviewed all randomised controlled trials about the effect of colchicine in preventing recurrence of pericarditis in
people with pericarditis. We found four trials involving 564 participants, who were followed up for at least 18 months. Two studies
examined the use of colchicine in people with recurrent pericarditis and two examined the use of colchicine in people with a ﬁrst
episode of pericarditis. The evidence is current to August 2014.
The trials showed that people taking colchicine have a lower risk of developing pericarditis recurrence and a higher proportion experience
symptom relief. It is expected that at 18 months, one pericarditis recurrence can be avoided for every four people receiving colchicine
with NSAIDs rather than NSAIDs alone. Adverse effects were reported in all trials and affected 15 people (9%) of the 162 taking
colchicine. Adverse effects included abdominal pain, nausea and vomiting.
Two studies were designed so that participants knew the type of intervention they were taking and people in the comparison group had
no dummy pill. The results of these studies could exaggerate the effects of the drug.
The evidence suggests beneﬁcial effects of colchicine in preventing recurrence of pericarditis, however this is based on a limited number
of small trials. More trials are currently being done and we await their results to see if the beneﬁts of colchicine can be further conﬁrmed.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Time to recurrence of pericarditis
Outcomes Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Recurrent pericarditis
Chest pain + (ECG changes +/-
echocardiographic changes +/-
raised inflammatory markers)
Intervention: colchicine with
NSAID; Comparison: NSAID
alone
Follow-up: median 18 months
Setting: multicentre secondary
care
HR 0.37
(0.24 to 0.58)
204
(2 studies)
moderate1
Acute pericarditis
Chest pain + (ECG changes +/-
echocardiographic changes +/-
raised inflammatory markers)
Intervention: colchicine with
NSAID; Comparison: NSAID
alone
Follow-up: median 18 months
Setting: multicentre secondary
care
HR 0.40
(0.27 to 0.61)
360
(2 studies)
moderate1
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk
(and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: Confidence interval; ECG: electrocardiography; HR: Hazard ratio; NSAID: non-steroidal anti-inflammatory drug
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
Very low quality: We are very uncertain about the estimate.
1 High risk of bias in blinding domain.
B A C K G R O U N D
Description of the condition
Definitions
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Pericarditis is the inﬂammation of the pericardium, the membra-
nous sac surrounding the heart. Acute pericarditis is idiopathic
without an obvious aetiology in 80% to 90% of cases but has a
presumed viral origin (Dudzinski 2012). Other causes include tu-
berculosis, or bacterial and neoplastic diseases that are more com-
mon in low-income countries (Zayas 1995).
Recurrent pericarditis is both themost common andmost trouble-
some complication of acute pericarditis and is mostly idiopathic.
This is because the exact cause of the recurrence of pericarditis is
not known, but appears to be autoimmune as indicated by the
presence of autoantibodies and response to steroids (Cantarini
2013). There are two types of recurrent pericarditis, intermittent
or incessant. In the incessant type, discontinuation of NSAIDs
usually causes a relapse in less than six weeks. In the intermittent
type, people have varying symptom-free intervals, usually longer
than six weeks, without therapy (Soler-Soler 2004).
Incidence
The actual incidence of acute pericarditis in unknown, but it is esti-
mated to be 28 cases per 100,000 population/year (Imazio 2008a).
It is responsible for 4% of all causes of chest pain (Launbjerg 1996)
and 0.1% of all hospitalisations (Pölzl 2011). Recurrent pericardi-
tis can occur in up to 20% to 30% of people who have experi-
enced acute pericarditis (Fowler 1990; Adler 1998); this ﬁgure in-
creases to 50% after the ﬁrst recurrence (Imazio 2005a). The rate
of recurrence varies and can be a single episode in some people,
however, other people can experience more frequent episodes over
many years. Almost 45% of people experience two episodes, 40%
have between three and ﬁve episodes, and 10% have more than
ﬁve episodes (Soler-Soler 2004; Shabetai 2005).
Presentation and diagnosis
The manifestation of acute pericarditis is a pleuritic chest pain
with a sign or symptom marking the activity of the disease, such
as fever, a pericardial rub, electrocardiography (ECG) changes
(a widespread ST-segment elevation or PR-segment depression),
pericardial effusion and raised inﬂammatory markers (erythrocyte
sedimentation rate or C-reactive protein (CRP)) (Spodick 2003;
Troughton 2004). Acute pericarditis is diagnosed if at least two of
these manifestations are met (Dudzinski 2012).
Recurrent pericarditis is a repeat episode of acute pericarditis and
can have similar symptoms, although it tends to be milder (Soler-
Soler 2004; Adler 2011). There are no uniform diagnostic criteria
for recurrent pericarditis (Imazio 2007), however, observational
studies identiﬁed pleuritic chest pain, increased CRP and ECG
changes as theminimumcriteria for diagnosing a recurrent episode
of acute pericarditis (Brucato 2006a; Khandaker 2010).
Prognosis
The ﬁrst relapse usually occurs within 18 months after the ini-
tial pericarditis episode (Imazio 2005a; Imazio 2005b). However,
people can have many relapses that manifest as severe chest pain
lasting from several hours to several days. These painful and dis-
abling episodes impair quality of life and cause a severe clinical
problem (Soler-Soler 2004).
Acute and recurrent pericarditis can be complicated by life-threat-
ening consequences, such as pericardial effusion, tamponade or
constriction, which may increase mortality (Soler-Soler 2004;
Dudzinski 2012). These complications can occur in up to 3.5% of
people in recurrent pericarditis and evenmore frequently in people
with acute pericarditis (Imazio 2007). However, in the long term,
complications are rare and the prognosis of recurrent pericarditis
is good (Brucato 2006a).
Description of the intervention
Therapy of acute pericarditis should always be targeted as much
as possible to the underlying aetiology. In idiopathic pericarditis,
treatment aims to manage the symptoms of the acute episode and
to then prevent subsequent recurrences. For a long time, high-dose
steroids were the mainstay of treatment. Yet, high-dose steroids
caused numerous serious adverse effects (Shabetai 2005), and their
prolonged use has actually worsened the prognosis by increasing
the recurrence rate of pericarditis and lengthening the course of
the disease (Artom 2005; Imazio 2005b; Imazio 2008). Therefore,
identifying interventions with a safer adverse effect proﬁle was
essential in order avoid worsening the natural course of recurrent
pericarditis in other ways.
Episodes of pericarditis are currently treated with aspirin or other
NSAIDs and with steroids for refractory cases (Maisch 2004;
Soler-Soler 2004). Colchicine has been used for the prevention of
recurrences (Brucato 2006).
Colchicine has anti-inﬂammatory actions and antiproliferative ef-
fects (Robert 2009). It inhibits many of the functions of neu-
trophils, such as the adhesion to endothelium and the release of a
chemotactic factor from neutrophil lysosomes (Nuki 2008).
Colchicine is considered a safe treatment in the treatment dose (
Imazio 2007), however, in high doses, it hasmany toxic effects and,
in addition, it has a narrow therapeutic window (Robert 2009).
The maximum therapeutic dose is 4 mg/24 hours, while a fatal
dose can be as low as 7mg/24 hours with a higher fatality rate if the
dose exceeds 0.5 - 0.8 mg/kg (Niel 2006; Cocco 2010; Finkelstein
2010). The parenteral use increases the risk of mortality and is
not used in clinical practice (Cocco 2010). Overdose is associated
with gastrointestinal, hepatic, renal, neuromuscular and cerebral
toxicity; bone marrow damage; and high mortality (Nuki 2008;
Finkelstein 2010). Colchicine is excreted mainly by the liver after
20 to 40 hours (Niel 2006) and can accumulate in people with
advanced liver disease (Rudi 1994).
The recommended dose of colchicine used in gout and in recurrent
pericarditis is 1 mg/day by oral administration (Adolph 1990;
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Adler 1998; Cocco 2010). Analgesia with colchicine is evident
within 12 to 14 hours of oral administration (Imazio 2009). The
most common adverse effects of the therapeutic dose are nausea,
vomiting, diarrhoea and abdominal pain (Niel 2006).
How the intervention might work
Colchicine is used in treating several inﬂammatory diseases such
as gout and familial Mediterranean fever (FMF) (Famaey 1988;
Niel 2006). Considering the possible autoimmune inﬂammatory
pathophysiology of recurrent pericarditis (Caforio 2010;Cantarini
2013), and its response to immunosuppressive and anti-inﬂam-
matory treatment (Marcolongo 1995), it is deemed acceptable and
logical to determine the effects of colchicine in the management
of recurrent pericarditis.
Why it is important to do this review
People with recurrent pericarditis can have a number of relapses
over many years, causing severe chest pain. These episodes of pain
limit both the functionality of patients and their quality of life,
causing both a social and psychological burden for the patients
and an economic burden on the hospitals taking care of them
(Soler-Soler 2004). The high incidence of recurrent pericarditis in
almost one-third of patients with acute pericarditis increases this
burden. Therefore, there is a need to ﬁnd and examine therapies
that decrease the number of recurrences.
Observational studies have shown that colchicine might be effec-
tive in treating recurrent pericarditis (Rodríguez de la Serna 1987;
Guindo 1990; Millaire 1994; Soler-Soler 2004; Imazio 2005b;
Brucato 2006). However, RCTs have only recently studied the
effect of colchicine on pericarditis. Therefore, there is a need to
systematically assess and critically appraise these trials in order to
obtain a more deﬁnite clinical answer for both patients and clini-
cians dealing with recurrent pericarditis.
A similar review has been published in the Heart journal (Imazio
2012). The main differences in our review are that we did not in-
clude postcardiac injury syndromes due to the different aetiology
and pathophysiology from acute or recurrent pericarditis. In ad-
dition, we analysed trials of acute pericarditis separately from tri-
als of recurrent pericarditis. We mention any differences between
our review and the Heart journal review explicitly in the section
’Agreements and disagreements with other studies or reviews’.
O B J E C T I V E S
To review all randomised controlled trials (RCTs) that assess the
effects of colchicine alone or combined, compared to any other
intervention to prevent further recurrences of pericarditis, in peo-
ple with acute or recurrent pericarditis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include RCTs with any length of follow-up, and we will
not impose any limitations on language or publication status.
Types of participants
1. People with acute idiopathic pericarditis treated to prevent
recurrences.
2. People with recurrent idiopathic pericarditis who have had
a documented episode of acute pericarditis, deﬁned by any
clinically valid diagnostic criteria such as described in the
’Description of the condition’ section and who have evidence of
recurrent pericarditis.
We included participants regardless of the number of pericarditis
recurrences, gender, age or ethnicity. We excluded acute or recur-
rent pericarditis that has bacterial or neoplastic causes, as in these
cases the known cause has to be treated andmanaged.We excluded
pericarditis as a result of postcardiac injury such as postmyocardial
infarction pericarditis (Dressler’s syndrome), postpericardiotomy
syndrome and post-traumatic pericarditis.
Types of interventions
1. Colchicine: in any dose, duration, intensity or means of
administration and alongside any additional therapy, on the
condition that the additional therapy was also used at the same
or similar dose in the control group.
2. Controls: any inactive control intervention (e.g. placebo or
no treatment) or any active control intervention (e.g. aspirin,
NSAIDs or steroids).
Types of outcome measures
We considered study eligibility regardless of the outcomes inves-
tigated or presented.
Primary outcomes
1. Time to ﬁrst recurrence expressed using hazard ratios (HRs).
2. Adverse effects of colchicine: general and speciﬁc during
treatment and on withdrawal of treatment.
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Secondary outcomes
1. Rate of ﬁrst recurrence of pericarditis as expressed by the
risk ratio (RR) at the following periods: short term (six months),
medium term (12 months) and long term (splitting > 12 months
into categories e.g. 18 months, 24 months).
2. Symptom relief during pericarditis episode.
Search methods for identification of studies
Electronic searches
SA and the Trials Search Co-ordinator (TSC) of the Cochrane
HeartGroup (CHG) searched the following databases on 4August
2014.
• Cochrane Central Register of Controlled Trials
(CENTRAL, Issue 7 of 12, 2014 on The Cochrane Library).
• MEDLINE (Ovid, 1946 to July week 4, 2014).
• EMBASE Classic and EMBASE (Ovid, 1947 to 2014 week
31).
• Conference Proceedings Citation Index- Science (CPCI-S)
on Web of Science (Thomson Reuters, 1990 to 5 August 2014).
The search did not include any language or time restriction. The
“not” Boolean was not used. The search strategies used can be
found in Appendix 1.
The RCT ﬁlter for MEDLINE is the Cochrane sensitivity-max-
imising RCT ﬁlter, and for EMBASE, terms as recommended in
the Cochrane Handbook for Systematic Reviews of Interventions have
been applied (Lefebvre 2011).
Searching other resources
We searched the following three databases of on-going trials on 5
August 2013.
• International Clinical Trials Registry Platform Search Portal
(apps.who.int/trialsearch/).
• ClinicalTrials.gov (www.clinicaltrials.gov).
• European Union Clinical Trials Register
(www.clinicaltrialsregister.eu).
We examined the references of all identiﬁed studies to look for
more studies. We contacted the ﬁrst author of each included study
for information about trials that had not been published.
Data collection and analysis
Selection of studies
Two review authors (SA, MQ) independently reviewed the titles
and abstracts identiﬁed from the searches done by SA and the
TSC. SA and MQ obtained full-text publications when neces-
sary, and determined eligibility independently. The opinion of a
third author (JBC) was sought when encountered with one of the
unpublished trials and dealing with studies of postcardiac injury
syndrome. We did not need to contact study authors for further
information.
Data extraction and management
Two authors (SA, GJI) independently assessed the methodolog-
ical quality and extracted data from the studies fulﬁlling the in-
clusion criteria. The data were extracted using an agreed data
extraction form. We included essential items mentioned in the
Cochrane Handbook for Systematic Reviews of Interventions table
7.3a (Higgins 2011a) regarding methods, participants, interven-
tion, outcomes and results. The data extraction form was piloted
by (SA) on one of the included studies.
’Summary of findings’ table
We used the GRADE approach, adopted by The Cochrane Col-
laboration, to interpret ﬁndings (Schünemann 2011).We used the
GRADE proﬁler (GRADEpro) (GRADEpro 2008) programme
to import data from Review Manager 5 (RevMan 2012), to create
the ’Summary of ﬁndings’ tables. The GRADE system involves an
assessment of the quality of a body of evidence for each individual
outcome. In GRADEpro the quality of evidence for each outcome
is separately rated as high, moderate, low and very low quality. The
rate of the outcomes of all randomised trials were regarded as high
and downgraded depending on: limitations in the design of the
selected studies, high risk of bias, indirectness of evidence, unex-
plained heterogeneity, imprecision of results, and high probability
of publication bias. The outcome-speciﬁc ratings were produced
in tables by GRADEpro and give information about the overall
quality of evidence from each included study. We selected all pri-
mary outcomes for inclusion in the ’Summary of ﬁndings’ table.
Assessment of risk of bias in included studies
Two review authors (SA, GJI) independently assessed the risk of
bias in each study using the ’Risk of bias’ tool of The Cochrane
Collaboration. A third author (JBC) was consulted about differ-
ences in opinion about grading the risk of bias in the blinding
domain.
Risk of bias for an outcome within a study (across domains)
The speciﬁc characteristics assessed included random sequence
generation, allocation concealment, blinding of participants, per-
sonnel and outcome assessors, incomplete outcome data, selective
reporting and other sources of bias.
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Risk of bias for an outcome across studies (e.g. for a meta-
analysis)
We summarised the risk of bias of the outcomes for each domain
included in the meta-analyses and incorporated judgements into
the ’Summary of ﬁndings’ tables. We expressed the risk of bias in
each domain using the following judgements: ’low risk’, ’high risk’
or ’unclear risk’ of bias, as recommended in theCochrane Handbook
for Systematic Reviews of Interventions table 8.5.d (Higgins 2011b).
Measures of treatment effect
We followed recommendations of the Cochrane Handbook for
Systematic Reviews of Interventions sections 9.2 and 9.4 (Higgins
2011c) for measuring the effects of different data types.
Time-to-recurrence
We used hazard ratios (HRs) with 95% conﬁdence intervals (CIs)
to express events such as time until the ﬁrst recurrence of pericardi-
tis. We used the methods described in Tierney 2007 to calculate
approximate hazard ratios.
Dichotomous data
We calculated the risk ratio (RR) with 95% CI for binary data
(i.e. recurrence rates, adverse effects). We calculated the number
needed to treat (NNT) from the absolute risk reduction (ARR) if
available.
Continuous data
We did not encounter any continuous data.
Counts and rates
We expressed count data (i.e. recurrence rate of pericarditis) as rate
ratios.
Unit of analysis issues
Our primary outcome was any recurrence of pericarditis and our
unit of analysis was the patient. We did not encounter any cluster
trials, studies with multiple treatment groups or cross-over trials.
Dealing with missing data
There was no issues with missing data in the included studies.
Assessment of heterogeneity
Clinical heterogeneity
Clinical heterogeneity might be due to differences in the popula-
tion i.e. age or ethnicity, or differences in interventions i.e. differ-
ent doses, duration, intensity or delivery method, or due to differ-
ences in the way outcomes are measured, such as different crite-
ria for pericarditis recurrence. All studies with outlying situations
will be fully discussed. A subgroup analysis of different causes of
clinical heterogeneity is planned.
People with acute pericarditis and recurrent pericarditis have a dif-
ferent baseline risk for recurrence, as patients who already have
experienced recurrent episodes of pericarditis are more susceptible
to recurrence (Soler-Soler 2004; Shabetai 2005). Therefore, we
analysed the two patient groups separately for any outcome com-
paring recurrence rates, as speciﬁed in the protocol. We combined
outcomes of adverse effects and symptom relief for people with
acute and recurrent pericarditis as they are not affected by the risk
for recurrence.
Methodological heterogeneity
We investigated all included trials for unpredicted outlying meth-
ods. All included studies were methodologically comparable.
Statistical heterogeneity
We investigated statistical heterogeneity by visual inspection and
carrying out both the Chi2 test and the I2 test. The Chi2 test with
a small P value provides evidence of heterogeneity. However, be-
cause of the low power of the Chi2 test we used a P value of 0.1 to
determine statistical signiﬁcance. We used the I2 statistic to quan-
tify statistical inconsistency and assess the impact of heterogeneity
on the meta-analysis. An I2 > 50% was set to demonstrate high
heterogeneity.
Assessment of reporting biases
As the number of included studies was less than ten studies we did
not attempt to use the funnel plot test, because it would have too
low a power to distinguish chance from real asymmetry (Sterne
2011).
Data synthesis
We pooled data in meta-analyses where they were available and it
was clinically acceptable to do so. We used Review Manager soft-
ware formeta-analyses (RevMan 2012). For the statistical analyses,
we used the ﬁxed-effect model with 95% CI as the main analysis.
In addition, we undertook a sensitivity analysis using the random-
effects model as per protocol.
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Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We intended to do a subgroup meta-analyses for:
1. dosage of colchicine used; and
2. age of patient (children and adults).
However, there was not enough data to perform any of the sub-
group analyses.
2. Investigation of heterogeneity
We did not encounter high levels of heterogeneity.
Sensitivity analysis
1. We performed a sensitivity analyses of ﬁxed-effect versus
random-effects, as per protocol.
2. It was not possible to perform a sensitivity analyses of
studies judged to be at high risk of bias.
R E S U L T S
Description of studies
Results of the search
We identiﬁed a total of 732 articles from the search of CENTRAL,
MEDLINE, EMBASE,Web of Science and clinical trial registers.
Removal of duplicates left 481 articles for screening, including 68
abstracts of conferences. From the 532 screened articles we ex-
cluded 464 and retrieved 68 full papers. A further 63 were not
RCTs or were RCTs not related to our review. This left four tri-
als that met the inclusion criteria (Imazio 2005; Imazio 2005a;
Imazio 2011; Imazio 2013) and one study awaiting classiﬁcation
(Imazio 2014). We did not identify any additional eligible trials
after scanning the reference lists of full-text papers.
The process with reasons for exclusions is described in Figure 1
and a list of excluded trials is given in the table ’Characteristics of
excluded studies’.
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Figure 1. Study flow diagram.
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Additionally, we identiﬁed one on-going RCT registered on the
European Union Clinical Trials Register EUCTR2009-011258-
16-ES.
Included studies
The four included trials were conducted between 2005 and 2013.
The trials, Imazio 2005 and Imazio 2005a were done by the same
research group and some members of this research group were
also involved in Imazio 2011 and Imazio 2013. All four studies
were parallel design, RCTs. Two studies were double-blind (Imazio
2011; Imazio 2013) and the other two (Imazio 2005; Imazio
2005a) were open-label. Two studies addressed people with recur-
rent pericarditis (Imazio 2005a; Imazio 2011), whereas (Imazio
2005; Imazio 2013) addressed patients with acute pericarditis.
The mean follow-up of all included studies was from 20 to 24
months. All studies were conducted in secondary care settings in
Italy. Imazio 2011 and Imazio 2013 aremulticentre studies, Imazio
2005 was conducted in two health centres and Imazio 2005a was
conducted in one hospital. All trialswere done by the same research
group. All studies were published in English.
Population
We included a total of 564 participants in this review. Of these,
204 participants were recruited in the trials for recurrent pericardi-
tis and 360 for acute pericarditis. Only patients with a ﬁrst recur-
rence of pericarditis were recruited in Imazio 2005a and Imazio
2011. Diagnosed pericarditis was either idiopathic (80% to 85%)
or autoimmune (15% to 20%) in Imazio 2005, Imazio 2005a
and Imazio 2011). In Imazio 2013, 77% of included participants
had idiopathic pericarditis, 3% autoimmune pericarditis and 20%
had postcardiac injury syndrome. Although we initially decided
to exclude patients with postcardiac injury syndrome, it was not
possible in Imazio 2013 to analyse data of patients with idiopathic
pericarditis only.
All included participants had chest pain as themain symptom.The
main signs were ECG changes (70% to 85%), pericardial effusion
(60% to 68%) and pericardial rub (20% to 35%). The number
of female participants was slightly higher in Imazio 2005, Imazio
2005a and Imazio 2011, making up 52% to 57% in Imazio 2005
and Imazio 2011 and 62% to 69% in Imazio 2005a. In Imazio
2013, female participants made up 40%.
The mean ages in years (standard errors are given in brackets) of
the included patients in each group are as follows.
• Imazio 2005: control 57.2 (19.6), colchicine 56.5 (18.2).
• Imazio 2005a: control 51.2 (16.3), colchicine 56.4 (16.9).
• Imazio 2011: control 47.3 (14.4), colchicine 47.9 (15.4).
• Imazio 2013: control 50.7 (17.5), colchicine 53.5 (16.2).
No study included children, elderly people, pregnant or lactating
women or women of childbearing age who were not using con-
traception. People with severe liver disease, serum creatinine levels
greater than 221 µmol/L (2.5 mg/dL), gastrointestinal disease; or
known hypersensitivity to colchicine were also excluded.
Baseline characteristics of participants in the trials are shown in
Table 1.
Intervention
The intervention was oral colchicine tablets in all included trials.
Colchicine was given at a loading dose of 1 mg every 12 hours
for the ﬁrst day of treatment, except Imazio 2013 which did not
have a loading dose. Amaintenance dose of 0.5 mg twice daily was
then continued for six months in Imazio 2005a and Imazio 2011
and three months in Imazio 2005 and Imazio 2013. People who
weighed less than 70 kg, had the loading dose changed to 0.5 mg
every 12 hours, followed by a maintenance dose of 0.5 mg once
daily.
Participants in both the intervention and control group in all in-
cluded studies received oral aspirin at a dose of 800 mg every six
to eight hours for seven to 10 days. The dosage of aspirin was then
gradually tapered down over a period of three to four weeks. In
Imazio 2011 and Imazio 2013, ibuprofen 600 mgwas additionally
offered as an alternative to aspirin. People who had contraindica-
tions to aspirin received prednisone for four weeks with gradual
tapering down. The dose of prednisone given was 1 to 1.5 mg/
kg in Imazio 2005 and Imazio 2005a, and 0.2 to 0.5 mg/kg in
Imazio 2011 and Imazio 2013.
Participants in both the intervention and control group also re-
ceived a proton-pump inhibitor (PPI) while they were on aspirin
or another NSAID. The dose of the PPI was not mentioned in
the studies.
The control group in Imazio 2011 and Imazio 2013 also received
placebo tablets that were identical in colour, shape, and taste to
the colchicine tablets and were provided in identical packs. The
control group in Imazio 2005 and Imazio 2005a did not receive a
placebo.
Outcomes
The recurrence of pericarditis was reported in all studies using
survival analysis with Kaplan-Meier event-free curves. The end-
point chosen in the studies was the rate of pericarditis recurrence
at 18 months. Recurrences were deﬁned in all studies by chest
pain with at least one other objective outcome measure such as
pericardial friction rub, widespread ST-segment elevation or PR-
segment depression on ECG, new or worsening pericardial effu-
sion on echocardiography and raised inﬂammatory markers such
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as white blood cell count, erythrocyte sedimentation rate (ESR)
or C-reactive protein (CRP).
All studies reported on the type and number of adverse events.
Relief from the symptoms of pericarditis at 72 hours was a reported
secondary outcome in all included studies. Additonally, Imazio
2011 and Imazio 2013 reported remission rate at one week, num-
ber of recurrences, time to ﬁrst recurrence, disease-related hospi-
talisation, cardiac tamponade, and rates of constrictive pericarditis
as other secondary outcomes.
The main characteristics of the included studies are summarised
in the table Characteristics of included studies.
All trials stated that outcomes were assessed and measured by
blinded expert cardiologists.
Excluded studies
The main reason for excluding studies was if they were not
RCTs and if they were literature reviews. We excluded two RCTs
(Finkelstein 2002; Imazio 2007b) as they were of postpericardec-
tomy syndrome which is not relevant to this systematic review.
The main characteristics of the excluded studies are in the table
’Characteristics of excluded studies’.
Risk of bias in included studies
In summary, Imazio 2011 and Imazio 2013 have been rated to
have a low risk of bias and Imazio 2005 and Imazio 2005a have
a moderate risk of bias. For details on the risk of bias in included
studies see ’Risk of bias’ table (Characteristics of included studies).
The overall risk of bias is presented graphically in Figure 2 and
summarised in Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Risk of bias across studies
We assessed the risk of bias for the reported outcomes using the
GRADE approach. We created ’Summary of ﬁndings’ tables us-
ing the Gradepro software. The quality of evidence was moder-
ate for outcomes of pericarditis recurrence and low quality for
total adverse events and symptom relief. Details of the risk of
bias across studies can be found in: Summary of ﬁndings for the
main comparison; Summary of ﬁndings 2; Summary of ﬁndings
3; Summary of ﬁndings 4; and Summary of ﬁndings 5.
Allocation
Randomisation
There was no description of how randomisation had been achieved
in Imazio 2005 and Imazio 2005a. In Imazio 2011 and Imazio
2013 participants were assigned to treatment groups by a central
computer-based automated sequence. In all studies, the sequence
for allocation was based on permuted blocks with a block size of
four.
Overall, the baseline characteristics of participants in all studies
in the intervention and control groups appeared similar after ran-
domisation, as shown in Table 1.
Allocation concealment
Allocation concealmentwas not reported in Imazio 2005 or Imazio
2005a. In Imazio 2011 and Imazio 2013 allocation concealment
was implemented by using sequentially numbered containers.
Imazio 2013 mentions that allocation was concealed from patients
and investigators.
Blinding
Blinding of participants and personnel
Both Imazio 2005 and Imazio 2005a had an open-label design.
Imazio 2011 and Imazio 2013 were double-blinded RCTs for both
participants and trial investigators. Additionally, the intervention
and control tablets were reported to be identical in colour, shape
and taste.
The control intervention was given for only four to ﬁve weeks in
all studies, whereas colchicine was given for six months (Imazio
2005a; Imazio 2011) or threemonths (Imazio 2005; Imazio 2013).
The study authors did not clarify if anything was given to the
control group after the control interventionwas stopped in order to
maintain blinding. The unequal duration of intervention between
the therapeutic and control groupmight have introduced blinding
bias for the participants.
Blinding of outcome assessors and data analysers
Clinical events were validated by an ad-hoc committee of expert
cardiologists who were blinded to participants’ allocation. Even
for Imazio 2005 and Imazio 2005a that had open-label designs,
recurrences of pericarditis were assessed by blinded outcome as-
sessors and required the presence of objective outcome measures
(raised inﬂammatory markers or ECG changes). Therefore, we
considered the risk of bias to be low. Data analyses were performed
by an external committee blinded to treatment allocation.
Incomplete outcome data
The risk of attrition bias seemed low. Intention-to-treat (ITT)
analysis was reported in all trials and all randomised participants
were included in the ﬁnal analyses and results. Colchicine therapy
was discontinued due to adverse effects (mainly gastrointestinal
symptoms) in ﬁve patients (8.3%) in Imazio 2005, three patients
(7%) in Imazio 2005a, ﬁve patients (8%) in Imazio 2011 and
fourteen patients (11.7%) in Imazio 2013. In the control group,
four (6%) people in Imazio 2011 discontinued therapy due to
adverse effects and ten people (8.3%) in Imazio 2013. Whereas
in Imazio 2005 and Imazio 2005a no one in the control group
withdrew from treatment. All patients who discontinued therapy
were followed up for recurrences and were included in all analyses.
Selective reporting
All reported outcomes were clinically relevant.
All studies were done to assess the rate of recurrence of pericarditis
with colchicine therapy and this has been reported as the main
outcome in all studies.
The secondary outcome of symptom persistence at 72 hours was
subjectively chosen by the researchers. Symptoms were not re-
ported at any point in time before or after the studied 72 hours. It
was not possible to ensure that this time point was decided on be-
fore the trials were done or because it showed the most favourable
results. Therefore, we considered the outcome of symptom relief
to be of high risk of bias for selective reporting.
Other potential sources of bias
No potential threats to validity had been detected, such as early
trial termination or any imbalance in the baseline characteristics
of the colchicine or control groups.
No declarations of conﬂict of interest were made by the trial au-
thors. The funding source had been reported in Imazio 2011 to
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be the Italian National Healthcare System. Imazio 2005, Imazio
2005a and Imazio 2013 did not declare the funding source.
Effects of interventions
See: Summary of findings for the main comparison Time to
recurrence of pericarditis; Summary of findings 2 Adverse effects
of colchicine; Summary of findings 3 Recurrences in patients
with recurrent pericarditis; Summary of findings 4 Recurrence
rate in patients with acute pericarditis; Summary of findings 5
Symptom relief for pericarditis
Time-to-recurrence
The time-to-recurrence has been expressed in HRs. The log HRs
and their standard error have been obtained using the log-rank
analysis fromamethodprovided byTrivella 2012 [pers comm].We
calculated the HRs using the generic inverse variance methods in
Review Manager (RevMan 2012). We included two trials (Imazio
2005a; Imazio 2011)with 204participants in themeta-analysis for
participants with recurrent pericarditis over 18 months of follow-
up: HR 0.37; 95% CI (0.24 to 0.58); I2= 0%, ﬁxed-effect model
(Analysis 1.1).
We included two trials (Imazio 2005; Imazio 2013) with 360 par-
ticipants in the meta-analysis participants with acute pericarditis
over 18 months of follow-up: HR 0.40; 95% CI (0.27 to 0.61); I
2= 0%, ﬁxed-effect model (Analysis 1.2).
Adverse effects of colchicine
All included studies reported on adverse events and their type. All
adverse effects of colchicine were due to gastrointestinal intoler-
ance, mainly consisting of diarrhoea but also other effects such as
nausea, vomiting or abdominal pain. Two people in Imazio 2013
experienced hepatotoxicity (an elevation of aminotransferase lev-
els) and one person got alopecia.
Similarlymost adverse events in the control groupwere of gastroin-
testinal origin and one person in each Imazio 2011 and Imazio
2013 experienced hepatotoxicity. No serious adverse effects have
been reported.
In Imazio 2011 all adverse effects were recorded in the ﬁrst week of
treatment. No comment on the time of adverse events was made
in Imazio 2005, Imazio 2005a or Imazio 2013.
We pooled the results of 564 participants in all four included stud-
ies as they had similar baseline characteristics and the interven-
tions were given in similar doses.
Total adverse event
A total of 29 people (10%) in the colchicine group and 23 people
(8%) in the control group had adverse effects (RR 1.26; 95% CI
(0.75 to 2.12) (P = 0.38); I2 = 0%, ﬁxed-effect model (Analysis
2.1)). The absolute risk difference (ARD) for adverse effects be-
tween colchicine and NSAIDs was 2%.
Adverse effects causing withdrawal of therapy
A total of 27 people out of 282 (9.6%) in the colchicine group had
to stop therapy due to adverse effects. Almost everyone who had
adverse effects with colchicine decided to stop therapy (27 out of
29). In the control group, 14 participants (5%) decided to stop
therapy.
The RR of adverse effects necessitating the stop of therapy was
1.87; 95% CI (1.02 to 3.41), (P = 0.04); I2 = 5%, ﬁxed-effect
model (Analysis 2.2), the ARD was 4.6%.
Recurrence rate
The recurrence rates have been reported by all included studies in
a Kaplan-Meier survival curve. Ideally, the recurrence rate should
have been calculated using the individual patient data, however
as these were not available, the data for recurrence rate has been
extracted from the survival curves using the DigitizeIt software
(DigitizeIt 2012). The shortcomings of data from Kaplan-Meier
curves is that it ignores the censored observations as it is not known
whether the outcome event occurred after follow-up ended. The
Kaplan-Meier curves do not show how many patients had the
recurrence with each drop in the survival-curve. Additionally, it
does not take into account the time for the event to happen as
participants may have joint the trial at different times (Altman
1991). This might result in some inaccuracies in the results.
The RR was calculated for the recurrence rates at time points of 6
months, 12 months and 18 months.
Recurrence rate in people with recurrent pericarditis
The recurrence rate for participants with recurrent pericarditis was
reported in Imazio 2005a and Imazio 2011. We combined the
data of 204 participants of both trials to calculate the RR.
Meta-analysis for recurrences in participants with recurrent peri-
carditis at 6 months: RR 0.28; 95% CI (0.17 to 0.47); I2= 0%,
ﬁxed-effect model (Analysis 3.1).
Meta-analysis for recurrences in participants with recurrent peri-
carditis at 12 months: RR 0.36; 95% CI (0.23 to 0.56); I2= 56%,
ﬁxed-effect model (Analysis 3.2).
Meta-analysis for recurrences in participants with recurrent peri-
carditis at 18 months: RR 0.38; 95% CI (0.25 to 0.58); I2= 0%,
ﬁxed-effect model (Analysis 3.3).
The total number of people who had one further recurrence at
18 months in the colchicine group was 21 of 102 (21%) and 55
of 102 (54%) in the NSAIDs group. The ARD was 23%. The
number needed to treat (NNT) to prevent one recurrence was 4.4.
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Recurrence rate in people with acute pericarditis
The recurrence rate for participants with acute pericarditis was
reported in Imazio 2005 and Imazio 2013. We combined the data
of 360 participants of both trials to calculate the RR.
At 6 months the RR was 0.36; 95% CI (0.23 to 0.58) (Analysis
4.1). At 6 months, 20 patients (11%) in the colchicine group and
55 patients (31%) in the control group had a ﬁrst recurrence. The
ARD was 20%.
At 12 months the RR was 0.40; 95% CI (0.26 to 0.61) (Analysis
4.2). At 12 months, 24 patients (13%) in the colchicine group
and 60 patients (33%) in the control group had a ﬁrst recurrence.
The ARD was 20%.
At 18 months the RR was 0.41; 95% CI (0.28 to 0.61) (Analysis
4.3). At 18 months, 27 patients (15%) In the colchicine group
and 66 patients (37%) in the control group had a ﬁrst recurrence.
The ARD was 22% and NNT to prevent one recurrence was 4.5.
Symptom relief
All included trials assessed the effect of colchicine on patients’
symptoms. Only symptom relief at 72 hours had been reported.
The pooled RR for symptom relief at 72 hours was 1.40; 95% CI
(1.26 to 1.56); I2= 0%, ﬁxed-effect model (Analysis 5.1).
Assessment of heterogeneity
All the studies were clinically homogenous and had patients with
similar baseline characteristics. All pooled estimates were statisti-
cally homogenous ( I2= 0%). The only exception was the pooled
effect of symptom relief which had an I2 = 89%. However, as there
is no clinical heterogeneity this might be due to the low number
of events in the control group in Imazio 2011.
Subgroup analysis
Wehave not performed any subgroup analysis. See the ’Differences
between protocol and review’.
We had intended to analyse any paediatric population as a sub-
group. However, no trial included people younger than 18 years.
A review of all non-randomised trials identiﬁed in the systematic
review search (Table 2) showed that colchicine has been tried in
children in 10 cases. In six children (Adler 1998; Yazigi 1998;
Jurko 2002) colchicine was effective in preventing further recur-
rences, however, it failed to show any effect in four other children
Raatikka 2003.
It was not possible to perform a subgroup analysis on the dose used
as all trials used the same dose of colchicine (1 mg/day). A review
of observational studies (Table 2) showed that the most frequent
dose used is 1 mg/d (10 of 15 studies). The rest of the reports used
doses varying from 0.25 to 2mg/d with or without a loading dose.
Sensitivity analysis
Due to the limited number of studies, it was not possible to con-
duct a sensitivity analysis for studies that we judged to be at high
risk of bias across at least one domain.
15Colchicine for pericarditis (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Adverse effects of colchicine for pericarditis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Colchicine
Total adverse effects
Patient reported
Follow-up: median 18 months
Study population RR 1.26
(0.75 to 2.12)
564
(4 studies)
⊕⊕
low1,2
82 per 1000 103 per 1000
(61 to 173)
Moderate
69 per 1000 87 per 1000
(52 to 146)
Adverse effects necessitat-
ing stop of therapy
Patient reported
Follow-up: median 18 months
Study population RR 1.87
(1.02 to 3.41)
564
(4 studies)
⊕⊕⊕
moderate2
50 per 1000 93 per 1000
(51 to 169)
Moderate
33 per 1000 62 per 1000
(34 to 113)
1 P value >0.05 (imprecise).
2 High risk of bias in blinding domain.
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Recurrences in patients with recurrent pericarditis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Colchicine
6 months
Chest pain + (ECG changes
+/- echocardiographic
changes +/- raised inflamma-
tory markers)
Follow-up: mean 6 months
Intervention: colchicine with
NSAID
Comparison: NSAID alone
Setting: multicentre sec-
ondary care
Study population RR 0.28
(0.17 to 0.47)
204
(2 studies)
⊕⊕⊕
moderate1,2
490 per 1000 137 per 1000
(83 to 230)
Moderate
481 per 1000 135 per 1000
(82 to 226)
12 months
Chest pain + (ECG changes
+/- echocardiographic
changes +/- raised inflamma-
tory markers)
Follow-up: median 12 months
Study population RR 0.36
(0.23 to 0.56)
204
(2 studies)
⊕⊕⊕
moderate1,2
520 per 1000 187 per 1000
(120 to 291)
Moderate
510 per 1000 184 per 1000
(117 to 286)
18 months
Chest pain + (ECG changes
+/- echocardiographic
changes +/- raised inflamma-
tory markers)
Follow-up: median 18 months
Study population RR 0.38
(0.25 to 0.58)
204
(2 studies)
⊕⊕⊕
moderate1,2
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539 per 1000 205 per 1000
(135 to 313)
Moderate
533 per 1000 203 per 1000
(133 to 309)
1 High risk of bias in blinding domain.
2 Low precision (small sample size and small number of events).
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Recurrence rate in patients with acute pericarditis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Colchcine
6 months
Chest pain + (ECG changes
+/- echocardiographic
changes +/- raised inflamma-
tory markers)
Follow-up: mean 6 months
Intervention: colchicine with
NSAID
Comparison: NSAID alone
Setting: multicentre sec-
ondary care
Study population RR 0.36
(0.23 to 0.58)
360
(2 studies)
⊕⊕⊕
moderate1
306 per 1000 110 per 1000
(70 to 177)
Moderate
292 per 1000 105 per 1000
(67 to 169)
12 months
Chest pain + (ECG changes
+/- echocardiographic
changes +/- raised inflamma-
tory markers)
Follow-up: median 12 months
Study population RR 0.4
(0.26 to 0.61)
360
(2 studies)
⊕⊕⊕
moderate1
333 per 1000 133 per 1000
(87 to 203)
Moderate
321 per 1000 128 per 1000
(83 to 196)
18 months
Chest pain + (ECG changes
+/- echocardiographic
changes +/- raised inflamma-
tory markers)
Follow-up: median 18 months
Study population RR 0.41
(0.28 to 0.61)
360
(2 studies)
⊕⊕⊕
moderate1
1
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367 per 1000 150 per 1000
(103 to 224)
Moderate
358 per 1000 147 per 1000
(100 to 218)
1 High risk of bias in blinding domain.
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Symptom relief for pericarditis
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of Participants
(studies)
Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
Control Colchcine
Symptom relief at 72 hours
Patient reported
Follow-up: median 7 days
Intervention: colchicine with
NSAID
Comparison: NSAID alone
Setting: multi centre sec-
ondary care
Study population RR 1.40
(1.26 to 1.56)
564
(4 studies)
⊕⊕
low 1,2
592 per 1000 829 per 1000
(746 to 924)
Moderate
617 per 1000 864 per 1000
(777 to 963)
1 Two open-label studies.
2 High risk of bias in selective reporting domain.
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D I S C U S S I O N
Summary of main results
The main results of the review compare the recurrence of peri-
carditis in people taking colchicine in addition to a NSAID such
as ibuprofen, aspirin or indomethacin to the recurrence of peri-
carditis in people taking a NSAID alone. We included four trials
with a total of 564 adult participants in this review. Two studies
(Imazio 2005a; Imazio 2011) included 204 participants with re-
current pericarditis and showed that colchicine is effective in pre-
venting further recurrences. The evidence shows that, the risk of
pericarditis recurrence in people with recurrent pericarditis, who
are taking colchicine, is 37% of the risk of recurrence in people not
taking colchicine over a period of 18 months. Thus, the average
reduction in recurrence of pericarditis with colchicine compared
to NSAIDs alone is 63% over a period of 18 months. The risk of
having a recurrent episode of pericarditis at 6, 12 and 18 months
is reduced by 72%, 64% and 63% respectively. It is expected that
at 18 months, one pericarditis recurrence can be avoided for ev-
ery four people receiving colchicine with NSAIDs rather than
NSAIDs alone.
Two studies (Imazio 2005; Imazio 2013) included 360 people
with acute pericarditis and assessed the recurrence of pericarditis.
The evidence shows that the average reduction in recurrence of
pericarditis with colchicine compared to NSAIDs alone is 60%
over a period of 18 months. The risk of having a recurrent episode
of pericarditis at 6, 12 or 18 months is reduced by 64%, 60% and
59% respectively.
The primary outcomes are summarised in the following table.
Risk of relapse without
colchicine
Risk of relapse with colchicine
over 18 months
No. patients with
adverse effects
for 100 treated
Acute pericarditis 20% to 30% (Fowler 1990; Adler
1998)
8% to 15% (Analysis 1.2, Analysis
4.3)
10
Recurrent pericarditis 40% to 50% (Soler-Soler 2004) 15% to 20% (Analysis 1.1,
Analysis 3.3)
10
Adverse events were reported in all studies. Combining the results
of all 564 participants showed a similar adverse events rate in both
the intervention and control group. All adverse events were related
to the gastrointestinal system. The adverse effects in the colchicine
group were almost twice more likely to be the cause of stopping
treatment than in the control group.
The review showed that colchicine is effective in reducing the
symptoms of pericarditis. The combined data of all studies shows
that symptoms of the pericarditis episode are reduced by up to
60% in the colchicine group compared to the control group.
We used GradePro to create a summary of the ﬁndings and quality
of the evidence (Summary of ﬁndings for the main comparison;
Summary of ﬁndings 2; Summary of ﬁndings 3; Summary of
ﬁndings 4; Summary of ﬁndings 5).
Overall completeness and applicability of
evidence
The two combined studies for acute pericarditis (Imazio 2005;
Imazio 2013) and for recurrent pericarditis (Imazio 2005a; Imazio
2011) were homogenous in methodology, patients baseline char-
acteristics, intervention duration and dose and outcomes. This
makes the combined result a robust estimate of effect, however
it might be limited as to how it can be generalised to different
populations (Berman 2002).
All participants in the included trials were Italians with a mean
age of 47 to 57 years. Consequently, the evidence has limited
applicability to children, elderly adults or people from an ethnicity
other than European.
Patients with several recurrences were not studied. Consequently,
it is possible that the studies represent a population with a lower
risk of recurrence and better response to therapy.The results of this
review, therefore might not apply to patients with resistant multi-
ple recurrences. Pregnant and lactating women or fertile women
not protected by a contraceptive method are also not represented
by the studies. In addition, people were excluded from the trials if
they were receiving or had previously received colchicine for any
indication. Therefore, results might not be applicable to patients
taking colchicine for any other medical condition such as gout.
People with abnormal liver function were also excluded, although
this might have been because of acute infections or medications
(Adler 2006).
The colchicine therapy duration of three months for acute peri-
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carditis and six months for recurrent pericarditis is debatable. It
was not possible to do a subgroup analysis for different doses or
therapy durations. In order to identify different regimes of dura-
tion and dose of treatment, we systematically identiﬁed and re-
viewed non-RCT publications. This search retrieved 15 reports
(Table 2). The duration of therapy ranged fromone or twomonths
to 18 months. The suggested duration of therapy in this review
might not apply to all patients in a clinical setting and different
durations might be needed for different patients.
The review of all non-randomised trials (Table 2) shows that a
loading dose has not always been used and that there is no universal
agreement on the dosage of the loading dose which ranged from
1 mg to 3 mg. This review could not assess the importance of the
loading dose, as a subgroup analysis or comparison with a trial
that has not used a loading dose was not possible.
Quality of the evidence
All included studies are RCTs. We judged the outcomes, study-
ing time to recurrence and recurrence rates, to be of a moderate
methodological quality using the GRADE approach (GRADEpro
2008).
All three included studies stated that they were randomised tri-
als but only Imazio 2011 adequately reported the randomising
method and the allocation sequence generation.
The Imazio 2011 trial had a double-blind design. Although du-
ration of therapies in the intervention and control group varied
largely, which might have undermined the blinding of partici-
pants, outcomes were determined by blinded assessors and ob-
jective outcome measures. Two studies, Imazio 2005 and Imazio
2005a, were open-label design without blinding of the partici-
pants or researchers, however both had blinded outcome assessors
and an external data analysis committee masked to intervention
allocation.
The comparator in all trials was either aspirin (800 mg) or pred-
nisolone in Imazio 2005 and Imazio 2005a or as an additional
alternative, ibuprofen in Imazio 2011. However in clinical prac-
tice, stronger NSAIDs such as ibuprofen, indomethacin or higher
aspirin doses (1000 to 2000 mg/d) tend to be used. This might
have positively affected the apparent beneﬁt of colchicine.
All included studies followed an intention-to-treat (ITT) approach
and every randomised participant was followed up and analysed.
The quality of evidence for symptom relief during the pericarditis
episode is of low quality. The time point chosen to assess the symp-
toms was subjectively chosen and symptoms were not reported
over a range of time, suggesting a high risk of selective report-
ing. Additionaly, it is not clear which symptoms were relieved or
to what extend the symptoms were reduced. No description was
made on how the symptoms were assessed or measured. Complete
study protocols were not available to make judgements regarding
the risk of selective reporting.
Potential biases in the review process
The review was conducted according to the previously published
protocol. Attempts have been made to minimise review bias by
having two authors independently perform the literature search,
study selection, data extraction and risk of bias assessment. Un-
fortunately, we were unable to obtain study protocols of the in-
cluded studies from the study authors. We were also unable to use
funnel plots to determine if there was any publication bias as we
only found four studies. It is unlikely that there are any published
randomised trials that have been overlooked in this review.
Agreements and disagreements with other
studies or reviews
The authors of the included trials (Imazio 2005; Imazio 2005a;
Imazio 2011) performed a systematic review of their studies, pub-
lished in the Heart journal (Imazio 2012). The main contrast with
this review is that they analysed all pericardial disease (acute peri-
carditis, recurrent pericarditis and postpericardial syndrome) in
one meta-analysis. Our approach was to exclude postpericardial
syndrome due to the different aetiology and pathophysiology than
that of acute or recurrent pericarditis. In addition, we decided not
to pool the trials of acute and recurrent pericarditis together as
there are signiﬁcant differences in the baseline risk for further re-
currence of pericarditis. In addition, our review included an in-
dependent risk of bias assessment involving authors not partici-
pating in the initial trial. This review includes the results of an
additional study (Imazio 2013) not included in the Heart journal
review Imazio 2012.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Colchicine as adjunctive therapy to NSAIDs is effective in reduc-
ing the number of further recurrences in patients with recurrent
pericarditis or acute pericarditis. However, data is limited and may
not be sufﬁcient to recommend routine use of colchicine for the
general pericarditis population. It has also been found that patients
with multiple resistant recurrences have not been represented in
any trials, and it is these patients that are in most need of a treat-
ment.
No severe adverse effects were reported and all adverse effects were
related to gastrointestinal sensitivity such as abdominal pain, diar-
rhoea and nausea or vomiting. Although we do not have deﬁnitive
evidence that colchicine increases the risk of adverse events overall,
it was associated with higher therapy withdrawal rates than the
control group.
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Implications for research
Pericarditis is a relatively commondiseasewhich can relapse and re-
cur despite treatment. This can cause frustration for both patients
and healthcare providers. Current research of the use of colchicine
includes two RCTs in people with acute pericarditis and two in
people with recurrent pericarditis. Another two on-going RCTs
are awaited.
New research should study participants not covered in the cur-
rent trials, such as people with multiple resistant pericarditis recur-
rences, elderly people and children. About 2 to 3 in 1000 hospi-
talised children experience episodes of pericarditis (Yazigi 1998). It
is therefore important to assess the efﬁcacy and safety of colchicine
in paediatric populations. In addition, trials looking at different
populations such as from a non-European background are neces-
sary. Other questions that need to be addressed are the optimal
therapy durations, loading and maintenance doses.
All existing trials of colchicine in pericarditis have been conducted
by similar research groups. Although this is not a risk of bias itself,
it is beneﬁcial to have trials undertaken by different researchers.
We know of one ongoing RCTs ( EUCTR2009-011258-16-ES)
registered on ClinicalTrials.gov and the EU Clinical Trials Reg-
ister seeking to address the use of colchicine in pericarditis. We
hope that with the results of the ongoing research, a more deﬁnite
conclusion can be given.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Imazio 2005
Methods Randomised controlled trial with an open-label design
Participants A sample of 120 people with a ﬁrst episode of acute pericarditis
Interventions Colchicine (1 to 2 mg on the ﬁrst day then 0.5 to 1.0 mg daily for 3 months) + Aspirin
800 mg or prednisolone 1.0 to 1.5 mg/kg/d
Comparator: Aspirin 800 mg or prednisolone 1.0 to 1.5 mg/kg/d
Outcomes Recurrence rate
Secondary end point was the rate of symptom persistence at 72 hours from treatment
onset
Notes Clinical setting: 2 Italian centres
Follow-up: mean of 24 months (range 8 to 39 months)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not mentioned
in detail. Randomisation was based on per-
muted blocks, with a block size of 4
Allocation concealment (selection bias) Unclear risk Notmentioned.However, permuted-block
randomisation might lead to selection bias
Blinding of participants and personnel
(performance bias)
Recurrence of Pericarditis
High risk Open-label design and the duration of
treatment in the colchicine group was
longer than the duration of treatment in
the non-steroidal anti-inﬂammatory drug
group. However, the outcome assessors
were blinded to treatment assignment and
the objective outcome measures limit the
effect of the participants knowing their in-
tervention regime and reduces the risk of
bias
Blinding of participants and personnel
(performance bias)
Adverse Effects
High risk Open-label design. There is a high risk of
bias as part of participants and personnel
were not blinded to the treatment and ad-
verse effects were reported subjectively by
the participants
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Imazio 2005 (Continued)
Blinding of participants and personnel
(performance bias)
Symptom Relief
High risk Open-label design. There is a high risk
of bias as part of participants and person-
nel were not blinded to the treatment and
symptom relief was reported subjectively by
the participants
Blinding of outcome assessment (detection
bias)
Recurrences of pericarditis
Low risk The outcome assessors for pericarditis re-
currences were blinded to treatment assign-
ment
Blinding of outcome assessment (detection
bias)
Adverse Effects
High risk Open-label design. Adverse effects were
reported subjectively by participants not
blinded to the intervention
Blinding of outcome assessment (detection
bias)
Symptom Relief
High risk Open-label design. Symptom relief was re-
ported subjectively by the participants not
blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses were performed by intention-to-
treat
No patient was lost to follow-up, and all
participants were analysed for outcomes ac-
cording to their original assigned groups
Selective reporting (reporting bias) Low risk All primary and secondary outcome have
been reported
The secondary end point “symptom persis-
tence at 72 hours” is chosen subjectively
A protocol with a prespeciﬁed statistical
analysis was not available
Similarity of baseline characteristics Low risk Participants in both the intervention and
control group were similar in demographic
and clinical characteristics
Co-interventions avoided or similar Low risk The cointervention used in the treatment
group was aspirin 800 mg or prednisolone
1.0 to 1.5 mg/kg/d. This intervention was
similar in the control group
Other bias Low risk Not found
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Imazio 2005a
Methods Randomised Controlled Trial with an open-label design
Participants A sample of 84 people with a ﬁrst episode of recurrent pericarditis
Interventions Colchicine (1 to 2 mg on the ﬁrst day then 0.5 to 1.0 mg daily for 6 months) + Aspirin
800 mg or prednisolone 1.0 to 1.5 mg/kg/d
Comparator: Aspirin 800 mg or prednisolone 1.0 to 1.5 mg/kg/d
Outcomes Recurrence rate of pericarditis
Secondary end point was the rate of symptom persistence at 72 hours from treatment
onset
Notes Clinical setting: Cardiology Department, Maria Vittoria Hospital, Torino
Follow-up: mean of 20 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not mentioned
in detail. Randomisation was based on per-
muted blocks, with a block size of 4
Allocation concealment (selection bias) Unclear risk Notmentioned.However, permuted-block
randomisation might lead to selection bias
Blinding of participants and personnel
(performance bias)
Recurrence of Pericarditis
High risk Open-label design and the duration of
treatment in the colchicine group was
longer than the duration of treatment in
the non-steroidal anti-inﬂammatory drug
group. However, the outcome assessors
were blinded to treatment assignment
which limits the effect of the participants
knowing their intervention regime and re-
duces the risk of bias
Blinding of participants and personnel
(performance bias)
Adverse Effects
High risk Open-label design. Open-label design.
There is a high risk of bias as part of partic-
ipants and personnel were not blinded to
the treatment and adverse effects were re-
ported subjectively by the participants
Blinding of participants and personnel
(performance bias)
Symptom Relief
High risk Open-label design. There is a high risk
of bias as part of participants and person-
nel were not blinded to the treatment and
symptom relief was reported subjectively by
the participants
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Imazio 2005a (Continued)
Blinding of outcome assessment (detection
bias)
Recurrences of pericarditis
Low risk The outcome assessors for pericarditis re-
currences were blinded to treatment assign-
ment
Blinding of outcome assessment (detection
bias)
Adverse Effects
High risk Open-label design. Adverse effects were
reported subjectively by participants not
blinded to the intervention
Blinding of outcome assessment (detection
bias)
Symptom Relief
High risk Open-label design. Symptom relief was re-
ported subjectively by the participants not
blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis. All participants
analysed in the group they were ran-
domised to. No missing data
Selective reporting (reporting bias) Low risk The primary and secondary outcome has
been reported
The secondary end point “symptom persis-
tence at 72 hours” is chosen subjectively
A protocol with a prespeciﬁed statistical
analysis was not available
Similarity of baseline characteristics Low risk Participants in both the intervention and
control group were similar in demographic
and clinical characteristics
Co-interventions avoided or similar Low risk The cointervention used in the treatment
group was aspirin 800 mg or prednisolone
1.0 to 1.5 mg/kg/d. This intervention was
similar in the control group
Other bias Low risk No
Imazio 2011
Methods Multicentre double-blind randomised controlled trial
Participants A sample of 120 people with a ﬁrst recurrence of pericarditis
Interventions Colchicine (1 to 2 mg on the ﬁrst day then 0.5 to 1.0 mg/d for 6 months)
+ Aspirin 800 mg to 1000 mg or ibuprofen 600 mg or prednisolone 0.2 to 0.5 mg/kg/d
Comparator: Aspirin 800 mg or ibuprofen 600 mg or prednisolone 0.2 to 0.5 mg/kg/d
Outcomes Recurrence rate at 18 months follow-up
The secondary end points were symptom persistence at 72 hours, remission rate at 1
week, number of recurrences, time to ﬁrst recurrence, disease-related hospitalisation,
cardiac tamponade, and rates of constrictive pericarditis
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Imazio 2011 (Continued)
Notes Clinical setting: 4 general hospitals in Italy (Maria Vittoria Hospital, Torino; Ospedali
Riuniti, Bergamo; San Maurizio Regional Hospital, Bolzano; and Ospedale SS Annun-
ziata, Savigliano)
Follow-up: mean of 20 months
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients randomly assigned to treatment
groups by a central computer-based auto-
mated sequence. Randomisation was based
on permuted blocks, with a block size of 4
Allocation concealment (selection bias) Low risk The random allocation sequence was im-
plemented by using sequentially numbered
containers
Blinding of participants and personnel
(performance bias)
Recurrence of Pericarditis
Low risk All participants and trial investigators were
blinded to randomised treatment
Placebo tablets were identical to colchicine
in colour, shape, and taste; premarked to
allow splitting into 2 equal parts; and pro-
vided in blister packs. However, interven-
tion was given for 6 months whereas the
control was given for 4 to 5 weeks only
Blinding of participants and personnel
(performance bias)
Adverse Effects
Low risk All adverse effects happened in the ﬁrst
week of the trial. At that time the interven-
tion and control were given under double-
blind conditions
Blinding of participants and personnel
(performance bias)
Symptom Relief
Low risk Symptom relief was assessed after 72 hours
of the trial under double-blind conditions
Blinding of outcome assessment (detection
bias)
Recurrences of pericarditis
Low risk All trial investigators were blinded to ran-
domised treatment. Data were collected by
using case report and clinical events adju-
dication forms
Blinding of outcome assessment (detection
bias)
Adverse Effects
Low risk Adverse effects were reported by patients
blinded to intervention and blinded trial
investigators assessed data by using case re-
port and clinical events adjudication forms
Blinding of outcome assessment (detection
bias)
Symptom Relief
Low risk Symptom relief was reported by patients
blinded to intervention and blinded trial
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Imazio 2011 (Continued)
investigators assessed data by using case re-
port and clinical events adjudication forms
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses were performed by intention-to-
treat
No patient was lost to follow-up, and all
participants were analysed for outcomes ac-
cording to their original assigned groups
Selective reporting (reporting bias) Low risk All primary and secondary outcome have
been reported
Some secondary end points are chosen sub-
jectively such as symptom persistence at 72
hours and remission rate at 1 week. There
was no rationale explained for choosing
those endpoints norwere outcomes around
the chosen end points reported. A protocol
with a prespeciﬁed statistical analysis was
not available
Similarity of baseline characteristics Low risk Participants in both the intervention and
control group were similar in demographic
and clinical characteristics
Co-interventions avoided or similar Low risk The cointervention used in the treatment
group was aspirin 800mg or ibuprofen 600
mg or prednisolone 0.2 to 0.5 mg/kg/d.
This has been similarly used in the control
group
Other bias Low risk Not found
Imazio 2013
Methods Multicentre double-blind randomised controlled trial
Participants A sample of 120 people with a ﬁrst recurrence of pericarditis
Interventions Colchicine was administered at a dose of 0.5 to 1.0 mg daily for 3 months + (800 mg of
aspirin or 600 mg of ibuprofen or prednisolone 0.2 to 0.5 mg/kg/d)
Comparator: 800 mg of aspirin or 600 mg of ibuprofen given orally every 8 hours for 7
to 10 days, followed by tapering during a period of 3 to 4 weeks or prednisolone 0.2 to
0.5 mg/kg/d for 2 weeks with gradual tapering)
Outcomes Recurrence rate at 18 months follow-up
Secondary end points were symptom persistence at 72 hours, remission within 1 week,
number of recurrences, the time to the ﬁrst recurrence, disease-related hospitalisation,
cardiac tamponade, and constrictive pericarditis
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Imazio 2013 (Continued)
Notes Settings: Five general hospitals in Northern Italy
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients randomly assigned to treatment
groups by a central computer-based auto-
mated sequence
Allocation concealment (selection bias) Low risk The random-assignment sequence was im-
plemented with the use of sequentially
numbered study-drug containers. All pa-
tients and investigators were unaware of
study-group assignments
Blinding of participants and personnel
(performance bias)
Recurrence of Pericarditis
Low risk All participants and trial investigators were
blinded to randomised treatment
Placebo tablets were identical to colchicine
in colour, shape, and taste; premarked to
allow splitting into 2 equal parts; and pro-
vided in blister packs. However, interven-
tion was given for 3 months whereas the
control was given for 4 to 5 weeks only
Blinding of participants and personnel
(performance bias)
Adverse Effects
Low risk All participants and trial investigators were
blinded to randomised treatment
Blinding of participants and personnel
(performance bias)
Symptom Relief
Low risk Symptom relief was assessed after 72 hours
of the trial under double-blind conditions
Blinding of outcome assessment (detection
bias)
Recurrences of pericarditis
Low risk All trial investigators were blinded to ran-
domised treatment. Data were collected by
using case report and clinical events adju-
dication forms
Blinding of outcome assessment (detection
bias)
Adverse Effects
Low risk All trial investigators were blinded to ran-
domised treatment. Data were collected by
using case report and clinical events adju-
dication forms
Blinding of outcome assessment (detection
bias)
Symptom Relief
Low risk Symptom relief was reported by patients
blinded to intervention and blinded trial
investigators assessed data by using case re-
port and clinical events adjudication forms
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Imazio 2013 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analyses were performed by intention-to-
treat
No patient was lost to follow-up, and all
participants were analysed for outcomes ac-
cording to their original assigned groups
Selective reporting (reporting bias) Low risk All primary and secondary outcome have
been reported
Some secondary end points are chosen sub-
jectively such as symptom persistence at 72
hours and remission rate at 1 week. There
was no rationale explained for choosing
those endpoints norwere outcomes around
the chosen end points reported. A protocol
with a prespeciﬁed statistical analysis was
not available
Similarity of baseline characteristics Low risk Participants in both the intervention and
control group were similar in demographic
and clinical characteristics
Co-interventions avoided or similar Low risk The cointervention used in the treatment
group was aspirin 800mg or ibuprofen 600
mg or prednisolone 0.2 to 0.5 mg/kg/d.
This has been similarly used in the control
group
Other bias Low risk Not found
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adler 1994 Not RCT
Adler 1998 Not RCT (case series)
Adler 1998a Not RCT (case series)
Artom 2005 Not RCT (case series)
Brucato 2006 Not RCT (case series)
Cacoub 2000 Not RCT (case series)
Finkelstein 2002 Outcome studied is prevention of postpericardiotomy syndrome not pericarditis
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(Continued)
Grande 1995 Not RCT (case series)
Guindo 1990 Not RCT (case series)
Imazio 2005b Not RCT
Imazio 2007b Outcome studied is prevention of postpericardiotomy syndrome not pericarditis
la Serna 1987 Not RCT (case series)
Millaire 1994 Not RCT (case series)
Raatikka 2003 Not RCT (case series)
Yazigi 1998 Not RCT (case series)
RCT - randomised controlled trial
Characteristics of studies awaiting assessment [ordered by study ID]
Imazio 2014
Methods Multicentre, double-blind, placebo-controlled, randomised trial
Participants Recurrent pericarditis
Interventions Colchicine with NSAIDs compared to NSAIDs alone
Outcomes Recurrence rate and symptom relief
Notes
Characteristics of ongoing studies [ordered by study ID]
EUCTR2009-011258-16-ES
Trial name or title EUCTR2009-011258-16-ES
Methods Open-label randomised controlled trial
Participants Patients with ﬁrst episode of acute pericarditis
Interventions Colchicine
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EUCTR2009-011258-16-ES (Continued)
Outcomes Incidence of recurrences
Starting date 18/05/2010
Contact information Dr. Jaime Sagrista Sauleda jsagrist@gmail.com
Notes http://apps.who.int/trialsearch/Trial.aspx?TrialID=EUCTR2009-011258-16-ES
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract˙number:2009-011258-16
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D A T A A N D A N A L Y S E S
Comparison 1. Time to recurrence
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to recurrence in people
with recurrent pericarditis
2 204 Hazard Ratio (Fixed, 95% CI) 0.37 [0.24, 0.58]
2 Time to recurrence in people
with acute pericarditis
2 360 Hazard Ratio (Fixed, 95% CI) 0.40 [0.27, 0.61]
Comparison 2. Adverse effects of colchicine
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total adverse effects 4 564 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [0.75, 2.12]
2 Adverse effects necessitating stop
of therapy
4 564 Risk Ratio (M-H, Fixed, 95% CI) 1.87 [1.02, 3.41]
Comparison 3. Recurrence rate in people with recurrent pericarditis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 6 months 2 204 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.17, 0.47]
2 12 months 2 204 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.23, 0.56]
3 18 months 2 204 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.25, 0.58]
Comparison 4. Recurrence rate in people with acute pericarditis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 6 months 2 360 Risk Ratio (M-H, Fixed, 95% CI) 0.36 [0.23, 0.58]
2 12 months 2 360 Risk Ratio (M-H, Fixed, 95% CI) 0.4 [0.26, 0.61]
3 18 months 2 360 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.28, 0.61]
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Comparison 5. Symptom relief
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Symptom relief at 72 hours 4 564 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [1.26, 1.56]
Analysis 1.1. Comparison 1 Time to recurrence, Outcome 1 Time to recurrence in people with recurrent
pericarditis.
Review: Colchicine for pericarditis
Comparison: 1 Time to recurrence
Outcome: 1 Time to recurrence in people with recurrent pericarditis
Study or subgroup Colchicine Control log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Imazio 2005a 42 -1.0083163 (0.3592106) 42 40.8 % 0.36 [ 0.18, 0.74 ]
Imazio 2011 60 -0.98104553 (0.2981424) 60 59.2 % 0.37 [ 0.21, 0.67 ]
Total (95% CI) 102 102 100.0 % 0.37 [ 0.24, 0.58 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 4.32 (P = 0.000015)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
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Analysis 1.2. Comparison 1 Time to recurrence, Outcome 2 Time to recurrence in people with acute
pericarditis.
Review: Colchicine for pericarditis
Comparison: 1 Time to recurrence
Outcome: 2 Time to recurrence in people with acute pericarditis
Study or subgroup Colchicine Control log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
N N (SE) IV,Fixed,95% CI IV,Fixed,95% CI
Imazio 2005 60 60 -1.1512647 (0.4) 27.8 % 0.32 [ 0.14, 0.69 ]
Imazio 2013 120 -0.81627922 (0.24806947) 120 72.2 % 0.44 [ 0.27, 0.72 ]
Total (95% CI) 180 180 100.0 % 0.40 [ 0.27, 0.61 ]
Heterogeneity: Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 4.31 (P = 0.000016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
Analysis 2.1. Comparison 2 Adverse effects of colchicine, Outcome 1 Total adverse effects.
Review: Colchicine for pericarditis
Comparison: 2 Adverse effects of colchicine
Outcome: 1 Total adverse effects
Study or subgroup Colchicine Control group Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005 6/42 3/42 13.0 % 2.00 [ 0.54, 7.47 ]
Imazio 2005a 5/60 4/60 17.4 % 1.25 [ 0.35, 4.43 ]
Imazio 2011 4/60 4/60 17.4 % 1.00 [ 0.26, 3.81 ]
Imazio 2013 14/120 12/120 52.2 % 1.17 [ 0.56, 2.42 ]
Total (95% CI) 282 282 100.0 % 1.26 [ 0.75, 2.12 ]
Total events: 29 (Colchicine), 23 (Control group)
Heterogeneity: Chi2 = 0.63, df = 3 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
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Analysis 2.2. Comparison 2 Adverse effects of colchicine, Outcome 2 Adverse effects necessitating stop of
therapy.
Review: Colchicine for pericarditis
Comparison: 2 Adverse effects of colchicine
Outcome: 2 Adverse effects necessitating stop of therapy
Study or subgroup Colchicine Control group Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005 5/60 0/60 3.3 % 11.00 [ 0.62, 194.63 ]
Imazio 2005a 3/42 0/42 3.3 % 7.00 [ 0.37, 131.47 ]
Imazio 2011 5/60 4/60 26.7 % 1.25 [ 0.35, 4.43 ]
Imazio 2013 14/120 10/120 66.7 % 1.40 [ 0.65, 3.03 ]
Total (95% CI) 282 282 100.0 % 1.87 [ 1.02, 3.41 ]
Total events: 27 (Colchicine), 14 (Control group)
Heterogeneity: Chi2 = 3.16, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 2.03 (P = 0.043)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
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Analysis 3.1. Comparison 3 Recurrence rate in people with recurrent pericarditis, Outcome 1 6 months.
Review: Colchicine for pericarditis
Comparison: 3 Recurrence rate in people with recurrent pericarditis
Outcome: 1 6 months
Study or subgroup Colchicine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005a 6/42 18/42 36.0 % 0.33 [ 0.15, 0.76 ]
Imazio 2011 8/60 32/60 64.0 % 0.25 [ 0.13, 0.50 ]
Total (95% CI) 102 102 100.0 % 0.28 [ 0.17, 0.47 ]
Total events: 14 (Colchicine), 50 (Control)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 4.75 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
Analysis 3.2. Comparison 3 Recurrence rate in people with recurrent pericarditis, Outcome 2 12 months.
Review: Colchicine for pericarditis
Comparison: 3 Recurrence rate in people with recurrent pericarditis
Outcome: 2 12 months
Study or subgroup Colchicine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005a 10/42 19/42 35.8 % 0.53 [ 0.28, 0.99 ]
Imazio 2011 9/60 34/60 64.2 % 0.26 [ 0.14, 0.50 ]
Total (95% CI) 102 102 100.0 % 0.36 [ 0.23, 0.56 ]
Total events: 19 (Colchicine), 53 (Control)
Heterogeneity: Chi2 = 2.26, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 4.48 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
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Analysis 3.3. Comparison 3 Recurrence rate in people with recurrent pericarditis, Outcome 3 18 months.
Review: Colchicine for pericarditis
Comparison: 3 Recurrence rate in people with recurrent pericarditis
Outcome: 3 18 months
Study or subgroup Colchicine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005a 10/42 21/42 38.2 % 0.48 [ 0.26, 0.89 ]
Imazio 2011 11/60 34/60 61.8 % 0.32 [ 0.18, 0.58 ]
Total (95% CI) 102 102 100.0 % 0.38 [ 0.25, 0.58 ]
Total events: 21 (Colchicine), 55 (Control)
Heterogeneity: Chi2 = 0.80, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
Analysis 4.1. Comparison 4 Recurrence rate in people with acute pericarditis, Outcome 1 6 months.
Review: Colchicine for pericarditis
Comparison: 4 Recurrence rate in people with acute pericarditis
Outcome: 1 6 months
Study or subgroup Colchicine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005 4/60 15/60 27.3 % 0.27 [ 0.09, 0.76 ]
Imazio 2013 16/120 40/120 72.7 % 0.40 [ 0.24, 0.67 ]
Total (95% CI) 180 180 100.0 % 0.36 [ 0.23, 0.58 ]
Total events: 20 (Colchicine), 55 (Control)
Heterogeneity: Chi2 = 0.47, df = 1 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 4.25 (P = 0.000021)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
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Analysis 4.2. Comparison 4 Recurrence rate in people with acute pericarditis, Outcome 2 12 months.
Review: Colchicine for pericarditis
Comparison: 4 Recurrence rate in people with acute pericarditis
Outcome: 2 12 months
Study or subgroup Colchicine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005 5/60 17/60 28.3 % 0.29 [ 0.12, 0.75 ]
Imazio 2013 19/120 43/120 71.7 % 0.44 [ 0.27, 0.71 ]
Total (95% CI) 180 180 100.0 % 0.40 [ 0.26, 0.61 ]
Total events: 24 (Colchicine), 60 (Control)
Heterogeneity: Chi2 = 0.59, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 4.23 (P = 0.000023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
Analysis 4.3. Comparison 4 Recurrence rate in people with acute pericarditis, Outcome 3 18 months.
Review: Colchicine for pericarditis
Comparison: 4 Recurrence rate in people with acute pericarditis
Outcome: 3 18 months
Study or subgroup Colchicine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005 5/60 20/60 30.3 % 0.25 [ 0.10, 0.62 ]
Imazio 2013 22/120 46/120 69.7 % 0.48 [ 0.31, 0.74 ]
Total (95% CI) 180 180 100.0 % 0.41 [ 0.28, 0.61 ]
Total events: 27 (Colchicine), 66 (Control)
Heterogeneity: Chi2 = 1.60, df = 1 (P = 0.21); I2 =38%
Test for overall effect: Z = 4.42 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [colchicine] Favours [control group]
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Analysis 5.1. Comparison 5 Symptom relief, Outcome 1 Symptom relief at 72 hours.
Review: Colchicine for pericarditis
Comparison: 5 Symptom relief
Outcome: 1 Symptom relief at 72 hours
Study or subgroup Colchicine Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Imazio 2005 53/60 38/60 22.8 % 1.39 [ 1.13, 1.73 ]
Imazio 2005a 38/42 29/42 17.4 % 1.31 [ 1.05, 1.64 ]
Imazio 2011 46/60 28/60 16.8 % 1.64 [ 1.21, 2.23 ]
Imazio 2013 97/120 72/120 43.1 % 1.35 [ 1.14, 1.60 ]
Total (95% CI) 282 282 100.0 % 1.40 [ 1.26, 1.56 ]
Total events: 234 (Colchicine), 167 (Control)
Heterogeneity: Chi2 = 1.60, df = 3 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 6.04 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours [control] Favours [colchicine group]
A D D I T I O N A L T A B L E S
Table 1. Baseline characteristics
Character-
istics
Imazio 2005 Imazio 2005a Imazio 2011 Imazio 2013
Colchicine Control Colchicine Control Colchicine Control Colchicine Control
Age 56.5 ± 18.2 57.2 ± 19.6 56.4 ± 16.9 51.2 ±16.3 47.9 ± 15.4 47.3 ± 14.4 53.5 ± 16.2 50.7 ± 17.5
Male
Female
46.7%
53.3%
43.3%
56.7%
38%
62%
31%
69%
43%
57%
48%
52%
59.2%
40.8%
61.7%
38.3%
Region Italy Italy Italy Italy Italy Italy Italy Italy
Pericarditic
chest pain
100% 100% 100% 100% 100% 100% 100% 99.2%
Pericardial
rub
35% 31.7% 36% 33% 20% 22% 36.7% 31.7%
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Table 1. Baseline characteristics (Continued)
ECG
changes
86.7% 88.3% 74% 69% n.a n.a 29.2% 21.7%
Pericardial
effusion
68.3% 63.3% 62% 64% 60% 58% 63.3% 68.3%
Cardiac
tamponade
1.6% 1.6% 2% 0 n.a n.a 1.7% 1.7%
Idiopathic
pericarditis
83.3% 85% 86% 81% 83% 80% 76.7% 77.5%
Autoim-
mune peri-
carditis
16.7% 15% 14% 19% 17% 20% 2.5% 3.3%
Steroid use
on index at-
tack
15% 16.6% 33% 38% 8% 10% n.a n.a
Table 2. Review of observational studies
Author and date Study type Participants Interventions Results Conclusion
Adler 1998 Case series 51 patients (36 men
and 15 women; mean
± SD age, 40.8 ± 18.
7 years) with recur-
rent pericarditis fol-
lowed up for < or = 10
years
Colchicine (1 mg/
day)
31 patients (60.7%)
remained recurrence-
free.
Drug withdrawal in
39 (76%) patients
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
Adler 1998a Two case reports a 26-year-old male
and a 2-year-old girl
with idiopathic peri-
carditis and pericar-
dial effusion
Colchicine (1 mg/
day) for 1 month
in the man and 6
months in the child
No recurrences in
24 months follow-up
in the man and 6
months follow-up in
the girl
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
Adler 1994 Case series 8 patients with recur-
rent pericarditis
Colchicine (1 mg/d) No recurrences were
noted during the 18
to 34 months of fol-
low-up. Drug with-
drawal was 50%
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
Brucato 2006 Controlled trial 58 pa-
tients with recurrent
pericarditis (34 men
Colchicine (1 mg/
day) for 18 months
No
further recurrence in
29/44 colchicine pa-
Colchicine is effec-
tive in the treatment
of recurrent
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Table 2. Review of observational studies (Continued)
and 24 women) were
followed up for an av-
erage of 8.1 years
tients (65.9%). Drug
withdrawal was 16%
pericarditis
Cacoub 2000 Case series 13 patients (7women
and 6 men) with re-
current pericarditis
Colchicine (1 to 2
mg/d) for 17 months
No
further recurrence in
10 (77%) patients
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
Grande 1995 Case series 5 patients (age 24
to 64 years) with
recurrent pericarditis.
Followed up for 24
months
Colchicine (1 mg/d)
for 18 months
There were no fur-
ther recurrences
of pericarditis during
the follow-up
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
Guindo 1990 Case series 9 patients (7men and
2 women; age, 18 to
64 years) with recur-
rent pericarditis fol-
lowed up for a mean
of 24.3months (10 to
54 month)
Colchicine (1 mg/d) No recur-
rences of pericarditis
were notedwithin the
follow-up
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
Guindo 2002 Controlled trial 51 patients with re-
current peri-
carditis (36 men, 14
women;mean age 40.
8 ± 18.7 years). Fol-
lowed up for a me-
dian of 36 months
Colchicine (1 to 2
mg/day)
(29 patients received
steroids before
colchicine)
6 of 22 (27%) pa-
tients who re-
ceived colchicine but
no steroids had recur-
rences
14 of 29 (48%) pa-
tients who were
treated with steroids
before colchicine had
recurrences
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
Imazio 2002 Case series 55 patients with re-
current pericarditis.
10 patients treated
with colchicine. The
rest were treated with
aspirin, or steroids, or
both. Followed up for
a mean of 36 months
Colchicine (loading
dose of 2 mg then
maintenance 1mg/d)
Remission in 9 of 10
pa-
tients (90%) treated
with colchicine com-
pared to 33 of 48
(69%) with aspirin
and 18 of 27 (67%)
with steroids
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
Imazio 2005b Controlled trial 35 patients with re-
current pericarditis.
Followed up for a
mean of 72 months
Colchicine (loading
dose of 2 mg then
1mg/dmaintenance)
for 6 months
Remission rate 32 of
35 patients (91.4%)
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
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Table 2. Review of observational studies (Continued)
Millaire 1994 Case series 19 patients (10 men,
nine women, age 46
± 7 years) who had
recurrent pericarditis.
Followed up for 32 to
44 months
Colchicine (loading
dose of 3 mg then
maintenance 1mg/d)
14 (74%) patients
had no recurrences
during a follow-up
period
Colchicine is effec-
tive in the treatment
of recurrent
pericarditis
la Serna 1987 Case series 3 patients with recur-
rent pericarditis. Fol-
lowed up for 15 to 35
months
Colchicine (1 mg/d)
for 2 months
No relapses through-
out the follow-up pe-
riod
Colchicine is useful
in the prevention of
recurrence of acute
pericarditis
Seferovic 2002 Controlled trial 17 into two groups.
Group 1 had 7 pa-
tients with idiopathic
chronic non-re-
curring pericarditis.
Group 2 had 10 pa-
tients with idiopathic
recurring pericarditis
Colchicine (loading
dose of 2 mg for one
week then a mainte-
nance dose of 1.5mg/
d) for 5 months
Disappearance of the
pericardial
effusion in 60% of
patients from group
2 compared to 14%
in group 1. Relief of
symptoms in 80% of
group 1 and 28% of
group 2
Colchicine is use-
ful in treating the
symptoms of recur-
rent pericarditis.
However, recurrences
were not reported
Raatikka 2003 Case series 4 children (aged 7 to
17 years) with recur-
rent pericarditis. Fol-
lowed up for 4 to 16
years (mean 8 years)
Colchicine (0.5 to 2
mg/d)
All patients had fur-
ther recurrences of
pericarditis
Colchicine did not
prevent pericarditis
relapses in children
Jurko 2002 Two case reports 2 children with a se-
vere form of idio-
pathic recurrent peri-
carditis
Colchicine No further relapses
occurred during a pe-
riod of 12 months in
the ﬁrst case and 9
months in the second
case
Colchicine is useful
in the prevention of
recurrence of peri-
carditis in children
Yazigi 1998 Case series 3 childrenwith recur-
rent pericarditis. Fol-
lowed up for 17 to 24
months
Colchicine (0.5 to 1.
5 mg loading dose
then 0.25 to 0.5 mg/
d maintenance) for 6
months
No relapses through-
out the follow-up pe-
riod
Colchicine is useful
in the prevention of
recurrence of peri-
carditis in children
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A P P E N D I C E S
Appendix 1. Search Strategies
CENTRAL (No. of results 23 )
#1 MeSH descriptor: [Pericarditis] explode all trees
#2 MeSH descriptor: [Pericardium] this term only
#3 pericard*
#4 #1 or #2 or #3
#5 MeSH descriptor: [Colchicine] explode all trees
#6 colchi*
#7 colchysat or colcine or colcrys or colgout or goutichine or goutnil or kolkicin or “nsc 757” or
tolchicine
#8 #5 or #6 or #7
#9 #4 and #8
MEDLINE OVID (No. of results 153)
1. exp Pericarditis/
2. Pericardium/
3. pericard*.tw.
4. or/1-3
5. exp Colchicine/
6. colchicin*.tw.
7. colchin.tw.
8. colchicum*.tw.
9. colchily.tw.
10. colchimedio.tw.
11. colchiquim.tw.
12. colchisol.tw.
13. colchysat.tw.
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14. colcine.tw.
15. colcrys.tw.
16. colgout.tw.
17. goutichine.tw.
18. goutnil.tw.
19. kolkicin.tw.
20. nsc 757.tw.
21. tolchicine.tw.
22. colchichin*.tw.
23. or/5-22
24. 4 and 23
25. randomized controlled trial.pt.
26. controlled clinical trial.pt.
27. randomized.ab.
28. placebo.ab.
29. drug therapy.fs.
30. randomly.ab.
31. trial.ab.
32. groups.ab.
33. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32
34. exp animals/ not humans.sh.
35. 33 not 34
36. 24 and 35
EMBASE OVID (No. of results 74)
1. exp pericarditis/
2. pericardium/
3. pericard*.tw.
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4. or/1-3
5. colchicine/
6. colchicin*.tw.
7. colchin.tw.
8. colchicum*.tw.
9. colchily.tw.
10. colchimedio.tw.
11. colchiquim.tw.
12. colchisol.tw.
13. colchysat.tw.
14. colcine.tw.
15. colcrys.tw.
16. colgout.tw.
17. goutichine.tw.
18. goutnil.tw.
19. kolkicin.tw.
20. nsc 757.tw.
21. tolchicine.tw.
22. colchichin*.tw.
23. or/5-22
24. 4 and 23
25. random$.tw.
26. factorial$.tw.
27. crossover$.tw.
28. cross over$.tw.
29. cross-over$.tw.
30. placebo$.tw.
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31. (doubl$ adj blind$).tw.
32. (singl$ adj blind$).tw.
33. assign$.tw.
34. allocat$.tw.
35. volunteer$.tw.
36. crossover procedure/
37. double blind procedure/
38. randomized controlled trial/
39. single blind procedure/
40. 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39
41. (animal/ or nonhuman/) not human/
42. 40 not 41
43. 24 and 42
Web of Science (No. of results 18)
# 3 #2 AND #1
# 2 TS=(colchi* or colchysat or colcine or colcrys or colgout or goutichine or goutnil or kolkicin or “nsc
757” or tolchicine)
# 1 TS= pericard*
Ongoing trials in (International Clinical Trials Registry Platform Search / ClinicalTrials.gov / www.clinicaltrialsregister.eu)
Search term: colchicine pericarditis
C O N T R I B U T I O N S O F A U T H O R S
S Alabed: Conceived the review, designed and wrote the protocol, searched for studies, screened search results for included studies, data
extraction and risk of bias assessment, co-ordinated the review, entered data into RevMan and wrote the review results.
JB Cabello: Conceived the review, co-ordinated the protocol and review, content and methodological expert.
GJ Irving: Data extraction and risk of bias assessment.
M Qintar: Screened search results for included studies.
A Burls: Contributed to the development of the review protocol and registration on The Cochrane Library, and reviewed and edited
the draft report.
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D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• Department of Continuing Education - University of Oxford, UK.
Providing access to journals and books
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We could not perform any subgroup analysis as available data were limited. We intended to assess the effect of high risk of bias in a
sensitivity analysis and publication bias in a funnel plot, however, there were not enough included trials to do so.
Our exclusion criteria was to exclude studies of postcardiac injury syndrome, however, we included Imazio 2013 which involved patients
with postcardiac injury syndrome. As Imazio 2013 included mainly idiopathic pericarditis (80%) we found it inappropriate to exclude
this study from our review.
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